{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T13:29:07Z","timestamp":1766582947385,"version":"3.48.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,24]]},"DOI":"10.7759\/cureus.100002","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T13:24:08Z","timestamp":1766582648000},"source":"Crossref","is-referenced-by-count":0,"title":["A Comparative Evaluation of the Effects of Saroglitazar and Pioglitazone on Hepatic and Metabolic Parameters in Type 2 Diabetes Mellitus With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)"],"prefix":"10.7759","author":[{"given":"Dayanidhi","family":"Meher","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sambit","family":"Das","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arun","family":"Choudhury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Devadarshini","family":"Sahoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandeep K","family":"Sahu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vishal","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Binod","family":"Prusty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bijay","family":"Ketan Das","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amogh S","family":"Chappalagavi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheenam","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vidhya","family":"Sreekumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"Diabetes - India. (2025). Accessed. April 30, 2025:  https:\/\/www.who.int\/india\/diabetes."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000913","article-title":"Epidemiology, screening, and co-management of type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease","volume":"4","author":"Qi X","year":"2024","unstructured":"Qi X, Li J, Caussy C, Teng GJ, Loomba R. Epidemiology, screening, and co-management of type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease. Hepatology. 2024, 4:6-8. 10.1097\/HEP.0000000000000913","journal-title":"Hepatology"},{"key":"ref3","doi-asserted-by":"crossref","DOI":"10.1177\/30502071231220779","article-title":"Diagnosis and management of MASLD: a metabolic perspective of a multisystem disease","volume":"1","author":"Ganakumar V","year":"2025","unstructured":"Ganakumar V, Halebidu T, Goroshi M, Ghatnatti V. Diagnosis and management of MASLD: a metabolic perspective of a multisystem disease. Int J Clin Metab Diabetes. 2025, 1:5-7.","journal-title":"Int J Clin Metab Diabetes"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.4103\/GHEP.GHEP_44_23","article-title":"Diabetes mellitus, obesity, and metabolic dysregulation as risk factors for metabolic dysfunction-associated steatotic liver disease","volume":"4","author":"Sridhar J","year":"2024","unstructured":"Sridhar J, Muthukrishnan M, Pranavi AS, Karthikeyan M, Venkataraman J, Jain M. Diabetes mellitus, obesity, and metabolic dysregulation as risk factors for metabolic dysfunction-associated steatotic liver disease. Gastroenterol Hepatol Endosc Pract. 2024, 4:73-6. 10.4103\/GHEP.GHEP_44_23","journal-title":"Gastroenterol Hepatol Endosc Pract"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis","volume":"149","author":"Vilar-Gomez E","year":"2015","unstructured":"Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al.. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 2015, 149:367-78. 10.1053\/j.gastro.2015.04.005","journal-title":"Gastroenterology"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/s41366-021-00788-4","article-title":"Weight loss and risk reduction of obesity-related outcomes in 0.5 million people: evidence from a UK primary care database","volume":"45","author":"Haase CL","year":"2021","unstructured":"Haase CL, Lopes S, Olsen AH, Satylganova A, Schnecke V, McEwan P. Weight loss and risk reduction of obesity-related outcomes in 0.5 million people: evidence from a UK primary care database. Int J Obes (Lond). 2021, 45:1249-58. 10.1038\/s41366-021-00788-4","journal-title":"Int J Obes (Lond)"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-022-00776-2","article-title":"Cardiorenal diseases in type 2 diabetes mellitus: clinical trials and real-world practice","volume":"19","author":"Lim LL","year":"2023","unstructured":"Lim LL, Chow E, Chan JC. Cardiorenal diseases in type 2 diabetes mellitus: clinical trials and real-world practice. Nat Rev Endocrinol. 2023, 19:151-63. 10.1038\/s41574-022-00776-2","journal-title":"Nat Rev Endocrinol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome PN","year":"2021","unstructured":"Newsome PN, Buchholtz K, Cusi K, et al.. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med. 2021, 384:1113-24. 10.1056\/NEJMoa2028395","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2011.04912.x","article-title":"Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis","volume":"35","author":"Boettcher E","year":"2012","unstructured":"Boettcher E, Csako G, Pucino F, Wesley R, Loomba R. Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2012, 35:66-75. 10.1111\/j.1365-2036.2011.04912.x","journal-title":"Aliment Pharmacol Ther"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31843","article-title":"Saroglitazar, a PPAR-\u03b1\/\u03b3 agonist, for treatment of NAFLD: a randomized controlled double-blind phase 2 trial","volume":"74","author":"Gawrieh S","year":"2021","unstructured":"Gawrieh S, Noureddin M, Loo N, et al.. Saroglitazar, a PPAR-\u03b1\/\u03b3 agonist, for treatment of NAFLD: a randomized controlled double-blind phase 2 trial. Hepatology. 2021, 74:1809-24. 10.1002\/hep.31843","journal-title":"Hepatology"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.2174\/13894501113149990199","article-title":"The first approved agent in the glitazar's class: saroglitazar","volume":"15","author":"Agrawal R","year":"2014","unstructured":"Agrawal R. The first approved agent in the glitazar's class: saroglitazar. Curr Drug Targets. 2014, 15:151-5. 10.2174\/13894501113149990199","journal-title":"Curr Drug Targets"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S49592","article-title":"Saroglitazar for the treatment of hypertriglyceridemia in patients with type 2 diabetes: current evidence","volume":"8","author":"Sosale A","year":"2015","unstructured":"Sosale A, Saboo B, Sosale B. Saroglitazar for the treatment of hypertriglyceridemia in patients with type 2 diabetes: current evidence. Diabetes Metab Syndr Obes. 2015, 8:189-96. 10.2147\/DMSO.S49592","journal-title":"Diabetes Metab Syndr Obes"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2020.10.051","article-title":"A phase 2 double blinded, randomized controlled trial of saroglitazar in patients with nonalcoholic steatohepatitis","volume":"19","author":"Siddiqui MS","year":"2021","unstructured":"Siddiqui MS, Idowu MO, Parmar D, et al.. A phase 2 double blinded, randomized controlled trial of saroglitazar in patients with nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2021, 19:2670-2. 10.1016\/j.cgh.2020.10.051","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-78342-x","article-title":"Saroglitazar in patients with non-alcoholic fatty liver disease and diabetic dyslipidemia: a prospective, observational, real world study","volume":"10","author":"Goyal O","year":"2020","unstructured":"Goyal O, Nohria S, Goyal P, Kaur J, Sharma S, Sood A, Chhina RS. Saroglitazar in patients with non-alcoholic fatty liver disease and diabetic dyslipidemia: a prospective, observational, real world study. Sci Rep. 2020, 10:21117. 10.1038\/s41598-020-78342-x","journal-title":"Sci Rep"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/jgh3.12878","article-title":"Efficacy and safety of saroglitazar in real-world patients of non-alcoholic fatty liver disease with or without diabetes including compensated cirrhosis: a tertiary care center experience","volume":"7","author":"Chaudhuri S","year":"2023","unstructured":"Chaudhuri S, Dutta A, Chakraborty SB. Efficacy and safety of saroglitazar in real-world patients of non-alcoholic fatty liver disease with or without diabetes including compensated cirrhosis: a tertiary care center experience. JGH Open. 2023, 7:215-20. 10.1002\/jgh3.12878","journal-title":"JGH Open"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/4287075","article-title":"Clinical case series of decrease in shear wave elastography values in ten diabetic dyslipidemia patients having NAFLD with saroglitazar 4\u2009mg: an Indian experience","volume":"2020","author":"Roy S","year":"2020","unstructured":"Roy S. Clinical case series of decrease in shear wave elastography values in ten diabetic dyslipidemia patients having NAFLD with saroglitazar 4\u2009mg: an Indian experience. Case Rep Med. 2020, 2020:4287075. 10.1155\/2020\/4287075","journal-title":"Case Rep Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2024.06.023","article-title":"Efficacy and safety of pioglitazone add-on in patients with type 2 diabetes mellitus inadequately controlled with metformin and dapagliflozin: a multicenter, randomized, double-blind, and placebo-controlled study","volume":"46","author":"Cho YK","year":"2024","unstructured":"Cho YK, Kim KS, Lee BW, et al.. Efficacy and safety of pioglitazone add-on in patients with type 2 diabetes mellitus inadequately controlled with metformin and dapagliflozin: a multicenter, randomized, double-blind, and placebo-controlled study. Clin Ther. 2024, 46:662-9. 10.1016\/j.clinthera.2024.06.023","journal-title":"Clin Ther"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.28.7.1547","article-title":"A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia","volume":"28","author":"Goldberg RB","year":"2005","unstructured":"Goldberg RB, Kendall DM, Deeg MA, et al.. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care. 2005, 28:1547-54. 10.2337\/diacare.28.7.1547","journal-title":"Diabetes Care"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/431867-a-comparative-evaluation-of-the-effects-of-saroglitazar-and-pioglitazone-on-hepatic-and-metabolic-parameters-in-type-2-diabetes-mellitus-with-metabolic-dysfunction-associated-steatotic-liver-disease-masld","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T13:24:09Z","timestamp":1766582649000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/431867-a-comparative-evaluation-of-the-effects-of-saroglitazar-and-pioglitazone-on-hepatic-and-metabolic-parameters-in-type-2-diabetes-mellitus-with-metabolic-dysfunction-associated-steatotic-liver-disease-masld"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,24]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.100002","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,24]]}}}